Amgen sweeps last BCMA BiTE standing out of pipeline

Exactly a year after resuming dosing on a bispecific that hits BCMA, Amgen is scrapping the drug altogether for “strategic reasons.”

The move — along with a separate decision to deprioritize acapatamab in favor of another PSMA-targeting drug, AMG 340, for the treatment of metastatic castrate-resistant prostate cancer — marks...

Click to view original post